Address the growing incidence of blindness in the world by developing and commercialising proven, therapeutically effective and cost competitive products for the treatment of debilitating eye diseases.
Our business focus is to develop state of the art and patented formulations of steroids for the treatment of ophthalmic diseases for both the front and back of the eye.
The global ophthalmology market is valued in excess of US$20B in annual sales. Key market drivers include an aging population as well as changes in diet and lifestyle globally leading to increases in diabetes and other metabolic disorders resulting in associated increases in disorders of the eye frequently leading to blindness.
These increasingly prevalent pathologies, resulting in part from the rapidly increasing incidence of age-related onset of diabetes in both the developed and developing world, are among the fastest growing causes of blindness.
Eye Co Pty Ltd.’s principal business activity is the early stage research and development of technologies for the treatment of diseases of the retina of the eye and the commercialization, marketing, and sale of the resultant products in Australia and internationally by globally capable third party partners.
Most recently, Eye Co commissioned a Phase 1b safety study in humans to ascertain the safety of its mineralocorticoid technology in the treatment of Geographic Atrophy associated with dry Age Related Macular Degeneration ( d-AMD).
The Company has also filed a patent application and is undertaking proof of concept studies relating to the composition and treatment of Age-Related Macular Degeneration (AMD) with hemp seed oil as a vehicle for the intravitreal presentation of ophthalmic steroids which remain problematic to handle for the treating physician in their current commercially available formats.